Retatrutide 10mg

Retatrutide 10 mg

Retatrutide (research designation LY3437943) is a synthetic, fatty-acid-acylated single-molecule triple receptor agonist engineered to engage the GIP, GLP-1, and glucagon (GCG) receptors simultaneously. It represents the newest generation of multi-incretin research peptides.

Research background

GLP-1 and GIP are incretin hormones that modulate insulin signaling and energy balance, while glucagon-receptor activity influences hepatic energy expenditure. Retatrutide was designed to study the combined effect of activating all three pathways with a single agonist, and features prominently in published metabolic and energy-regulation research.

Mechanism studied

Tri-agonism at the GIP / GLP-1 / glucagon receptors. Researchers investigate downstream effects on insulin-pathway signaling, lipid metabolism, and energy-expenditure markers in cell and animal models.

Specifications

Verify all specifications against the batch Certificate of Analysis (COA), available on request.

Reconstitution & handling (research use)

For laboratory use, reconstitute the lyophilized powder with bacteriostatic or sterile water to the desired stock concentration for research handling — e.g., adding 2 mL of bacteriostatic water to a 10 mg vial yields a 5 mg/mL stock solution. Store the lyophilized powder at −20 °C protected from light. Keep reconstituted material refrigerated (2–8 °C) and use within a short period. Avoid repeated freeze–thaw cycles.

Research Use Only (RUO). This product is supplied strictly for in-vitro laboratory research. It is not a drug, supplement, food, or medical device, and is not for human or veterinary consumption or any in-vivo use. No dosing, administration, or therapeutic guidance is provided or implied.